SCHEMBL3017755

SCHEMBL3017755

O=S(=O)(c1cccc(Cl)c1Cl)C1CCN(c2nc(-c3ccc(Cl)cc3)cs2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.52
RAB9A P51151 6/20 0.52
NPC1 O15118 5/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
SMN1; SMN2 Q16637 8/20 0.51
MAPK1 P28482 3/20 0.51
FFAR2 O15552 1/20 0.49
LMNA P02545 4/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 2/20 0.47
CTSS P25774 1/20 0.46
TSHR P16473 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HTT P42858 1/20 0.45
HSD17B10 Q99714 1/20 0.45
KDM1A O60341 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019121 0.93 LMNA (0.52) MAPTRAB9ANPC1CYP1A2CYP2C9
SCHEMBL3014279 0.92 SMN1; SMN2 (0.56) MAPTRAB9ANPC1CYP1A2CYP2C9
SCHEMBL3125799 0.92 SMN1; SMN2 (0.54) MAPTRAB9ANPC1CYP1A2CYP2C9
SCHEMBL3019657 0.92 MAPT (0.56) MAPTRAB9ANPC1CYP1A2CYP2C9
SCHEMBL2997891 0.90 AR (0.54) MAPTRAB9ANPC1CYP1A2CYP2C9
SCHEMBL3009532 0.89 SMN1; SMN2 (0.58) MAPTRAB9ANPC1SMN1; SMN2MAPK1
SCHEMBL3008381 0.89 LMNA (0.47) MAPTRAB9ANPC1CYP1A2CYP2C9
SCHEMBL3012646 0.89 SMN1; SMN2 (0.50) MAPTRAB9ANPC1CYP1A2CYP2C9
SCHEMBL3017359 0.89 SMN1; SMN2 (0.50) MAPTRAB9ANPC1CYP1A2CYP2C9
SCHEMBL3012821 0.88 LMNA (0.45) MAPTRAB9ANPC1CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.